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Early in the pathogenesis of type 2 diabetes mellitus
(T2DM), dysregulated glucagon secretion from
pancreatic a cells occurs prior to impaired glucose-
stimulated insulin secretion (GSIS) from b cells. How-
ever, whether hyperglucagonemia is causally linked
to b cell dysfunction remains unclear. Here we
show that glucagon stimulates via cAMP-PKA-
CREB signaling hepatic production of the neuropep-
tide kisspeptin1, which acts on b cells to suppress
GSIS. Synthetic kisspeptin suppresses GSIS in vivo
in mice and from isolated islets in a kisspeptin1 re-
ceptor-dependent manner. Kisspeptin1 is increased
in livers and in serum from humans with T2DM and
from mouse models of diabetes mellitus. Impor-
tantly, liver Kiss1 knockdown in hyperglucagonemic,
glucose-intolerant, high-fat-diet fed, and Leprdb/db
mice augments GSIS and improves glucose toler-
ance. These observations indicate a hormonal circuit
between the liver and the endocrine pancreas in
glycemia regulation and suggest in T2DM a sequen-
tial link between hyperglucagonemia via hepatic
kisspeptin1 to impaired insulin secretion.
INTRODUCTION
Glucagon and insulin are secreted by pancreatic a and b cells,
respectively, to precisely control blood glucose homeostasis.
An early hallmark of type 2 diabetes mellitus (T2DM) is dysregu-
lated glucagon secretion by pancreatic a cells. Nondiabetic
humans exhibit postprandial suppression of blood glucagon,Cwhile individuals with T2DM lack this suppression and may
even exhibit increased glucagon levels. In addition, studies in
subsets of patients with T2DM suggest that elevated glucagon
secretion occurs antecedent to b cell dysfunction (see D’Alessio
[2011] and references therein).
Upon binding to its receptor Gcgr, glucagon activates cellular
adenosine-30-50-cyclicmonophosphate (cAMP)-protein kinase A
(PKA) signaling to stimulate hepatic glucose production (HGP)
and cause hyperglycemia (Chen et al., 2005). While hyper-
glycemia stimulates insulin secretion from b cells, transgenic
upregulation of PKA activity in hepatocytes in mice results, as
expected, in increased HGP and hyperglycemia but paradoxi-
cally in impaired GSIS (Niswender et al., 2005). Consistent with
the idea that glucagon may be causally linked to b cell dysfunc-
tion are findingsmade during exogenous glucose infusion in rats,
where insulin secretion only fails after blood glucagon levels rise
and recovers upon glucagon inactivation by neutralizing anti-
serum (Jamison et al., 2011).
Based on these considerations for hyperglucagonemia and b
cell dysfunction in T2DM, we reasoned that independent of
HGP and hyperglycemia, glucagon signaling in the liver initiates
a process that impacts on GSIS. We tested this hypothesis by
comparing a mouse model of liver-specific PKA disinhibition
(L-DPrkar1a mice, see below) with a model of hyperglycemia
resulting from intravenous glucose infusion (D-glucose mice)
combined with array-based gene expression analysis for
secreted hepatic peptides, and we identified Kiss1, which en-
codes the neuropeptide kisspeptin1 to be upregulated in livers
of L-DPrkar1a—but not in D-glucose—mice and to be directly
stimulated by glucagon action via Gcgr on hepatocytes.
Kisspeptin1 has been described to be synthesized in the cen-
tral nervous system and to regulate hypothalamic gonadotropin
releasing hormone (GnRH) neurons and is processed to multiple
biologically active, N-terminally truncated fragments, including
kisspeptin 54 (K54), K14, K13, and K10, of which the latter exertsell Metabolism 19, 667–681, April 1, 2014 ª2014 Elsevier Inc. 667
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Figure 1. Comparison between L-Dprkar1a and D-Glucose Mice Identifies Kiss1
(A) (Left) Representative liver IB of prkar1afl/fl and L-Dprkar1a 4 days after adenovirus treatment. L-Dprkar1a mice show Prkar1a ablation and increased pCREB
(right). Liver IB from saline and D-glucose mice shows unaltered Prkar subtypes, Pkac, and pCREB.
(B) Fasting glucose levels in prkar1afl/fl, L-Dprkar1a, saline, and D-glucose mice. Prkar1afl/fl and saline mice have similar fasting glucose; D-glucose infusion
achieves fasting glucose similar to L-Dprkar1a mice (mean ±SEM; *p < 0.05).
(C) (Top) plasma glucose and (bottom) serum insulin during ipGTT in prkar1afl/fl, L-Dprkar1a, saline, and D-glucose mice. L-Dprkar1a mice exhibit impaired GT
(top) and GSIS (bottom). D-glucose mice have mildly impaired GT and robust GSIS. Prkar1a fl/fl and Sal-mice have similar GT and GSIS (mean ±SEM; *p < 0.05).
(D) qRT-PCR of indicated genes of gluconeogenic program in prkar1afl/fl, L-Dprkar1a, Sal-, and D-glucose-mouse livers. (Top) Gluconeogenic program is
upregulated in L-Dprkar1a as compared to prkar1afl/fl mice; (bottom) gluconeogenic program is downregulated in D-glucose as compared to saline mice
(mean ±SEM; *p < 0.05).
(legend continued on next page)
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An Endocrine Circuit of Liver to Islet Crosstalkfull biological effects (Seminara and Kaiser, 2005). In experi-
mental conditions, individual kisspeptin isoforms are reported
to suppress GSIS at nanomolar concentrations but stimulate
GSIS at micromolar concentrations (Hauge-Evans et al., 2006;
Silvestre et al., 2008). However, a (patho-) physiologic context
for circulating levels of kisspeptin1, its effects on b cell function
specifically via kisspeptin1 receptor (Kiss1R), and its interplay
with gluco-regulatory hormones are not understood.
Immunometric assays for kisspeptin have provided conflicting
information on kisspeptin levels in rodents and humans (Akinci
et al., 2012; Cetkovic et al., 2012; Horikoshi et al., 2003; Logie
et al., 2012), and mass-spectroscopy-based assays do not
provide exact information on circulating concentrations and
functional bioactivity of the complement of kisspeptin isoforms
in biological samples (Liu et al., 2013). Therefore, we have
used—in addition to immunoassays—a bioassay of kisspeptin1
action on GSIS from mouse islets, which either express Kiss1R
or selectively lack Kiss1R to reliably measure functional kisspep-
tin concentrations.
Using this assay, we find that synthetic kisspeptin inhibits
GSIS from cultured islets in a dose- and Kiss1R-dependent
manner at nanomolar concentrations. Furthermore, mice
rendered glucose intolerant by high-fat-content diet (HFD) or
leptin receptor defective diabetic (Leprdb/db) mice are hyper-
glucagonemic, exhibit increased liver kisspeptin1, and harbor
in their circulation functional kisspeptin bioactivity equivalent to
nanomolar concentrations of synthetic kisspeptin. In these
mice, selective liver kisseptin1 knockdown derepresses GSIS
and improves glucose tolerance (GT). Importantly, humans
with T2DM also exhibit increased liver and plasma kisspeptin1
levels. Furthermore, mice selectively lacking pancreas Kiss1R,
when fed a HFD, as compared to control counterparts, show
improved GT owing to increased GSIS.
These observations identify the liver as a site of regulated
kisspeptin1 synthesis, define a liver-to-islet endocrine circuit in
glucoregulation, and suggest a pathogenic mechanism in
T2DM, causally linking hyperglucagonemia via hepatic kisspep-
tin1 to insufficient insulin secretion. In addition, these findings
extend a potential for kisspeptin1 antagonism as a therapeutic
means to improve b cell function in diabetes mellitus.
RESULTS
Disinhibited PKA Activity in Liver Causes Impaired GSIS
Independent of Hyperglycemia
To mimic upregulated glucagon-cAMP-PKA signaling in vivo in
mouse liver independently of glucagon action in other tissues,
we selectively disinhibited liver PKA catalytic (PKAc) activity by
ablating hepatic PKA regulatory subunit 1A (Prkar1a) using the
CRE/LoxP method. Mice homozygous for floxed Prkar1a
(Prkar1afl/fl mice) (Kirschner et al., 2005) were treated by tail
vein injection with adenovirus driving CRE recombinase under(E) GSIS of WT mouse islets cultured in serum-free media conditioned with plas
L-Dprkar1a plasma at 1:10 but not at 1:100 dilution suppresses GSIS (mean ±SE
(F) Volcano plot of gene expression analysis of liver from prkar1afl/fl and L-Dprkar
mice.
(G) (Top) qRT-PCR of Kiss1 transcript and (bottom) IB in liver tissue from mice wi
shows increased Kiss1 transcript and kisspeptin protein. D-glucose mice show K
Ccontrol of the CMV promoter (Adv-CRE) to generate mice selec-
tively lacking liver Prkar1a (L-DPrkar1a mice). Control mice
received adenovirus expressing GFP (Adv-GFP).
Liver extracts harvested four days after injection from Adv-
CRE injected mice revealed a 90% reduction in Prkar1a protein
(Figure 1A), while other Prkar isoforms and Pkac levels remained
unaltered. As expected, L-DPrkar1a mice, as opposed to con-
trols, exhibited increased hepatic phosphorylation of cAMP-
response element binding protein (CREB) at serine 133 (pCREB),
an established PKAc target (Gonzalez andMontminy, 1989) (Fig-
ure 1A). Adv-CRE treatment did not affect Prkar1a expression
in islet, hypothalamus, adipose tissue, and skeletal muscle
(Figure S1A available online). Liver-specific PKA disinhibition
stimulated within 4 days hepatic expression of transcriptional
coactivators (Ppargc1a and Src1) and rate-limiting enzymes
(G6p and Pck1) of the gluconeogenic pathway (Louet et al.,
2010), which resulted in fasting hyperglycemia and notably also
in insufficient insulin secretion to correct glycemia during intra-
peritoneal glucose tolerance tests (ipGTT) (Figures 1C and 1D).
To assess whether hyperglycemia during 4 days is directly
associated with impaired GSIS, we generated amodel of chronic
hyperglycemia without hepatic PKA-CREB activation. Wild-type
(WT) mice were intravenously infused during 4 days with
D-glucose (D-glucose mice) to achieve fasting glucose levels
to match those measured in L-DPrkar1a mice (Figure 1B). Mice
infused with saline served as controls (saline mice). D-glucose
mice exhibited no change in liver pCREB (Figure 1A) and
reduced gene expression of the gluconeogenic program (Fig-
ure 1D). In contrast to L-DPrkar1a mice, D-glucose mice showed
increased GSIS and only mildly impaired GT (Figure 1C). Both
L-DPrkar1a and D-glucose mice showed similar increases in b
cell proliferation, as assessed by Ki67 expression (Figure S1E);
albeit, pancreas morphometric parameters or plasma glucagon
levels in L-DPrkar1a and D-glucose-infused mice did not change
during the short 4 day protocols (Figure S1B–S1H), excluding
differences in b or a cell mass or in glucagon action to account
for the differences in glucose homeostasis.
Selective PKA Disinhibition in Liver Induces Secreted
Neuropeptide Kiss1
The liver secretes factors that regulate pancreatic a or b cell
growth and that, in part, have been identified by liver gene
expression analyses (El Ouaamari et al., 2013; Longuet et al.,
2013; Yi et al., 2013). We reasoned that the liver may also secrete
a factor(s) that regulates b cell function and that may be altered in
L-DPrkar1a mice. We therefore treated isolated WTmouse islets
with serum-free media conditioned with plasma extracted from
L-DPrkar1a or control mice and examined GSIS at 10 mM
glucose. Plasma in 1:10 dilution from L-DPrkar1a, but not from
control, mice suppressed GSIS (Figure 1E). 1:100 diluted
L-DPrkar1a plasma did not suppress GSIS in this functional
bioassay. These observations suggested that PKA signaling inma of prkar1afl/fl or L-Dprkar1a mice. Prkar1afl/fl plasma does not affect GSIS.
M; *p < 0.05).
1a mice. Significant upregulation of Kiss1 transcript is detected in L-Dprkar1a
th indicated liver genetic complement or intravenous infusion. L-Dprkar1a liver
iss1 downregulation as compared to controls (mean ±SEM; *p < 0.05).
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Figure 2. Glucagon and Insulin Counterregulate Liver Kiss1 Expression
(A) qRT-PCR of Kiss1 and Pck1 in isolated mouse hepatocytes exposed to indicated treatment. Glucagon stimulates and insulin suppresses both genes
(mean ±SEM; *p < 0.05).
(B) qRT-PCR of Kiss1 in isolated mouse hepatocytes exposed to vehicle (DMSO) or fsk/IBMX. cAMP stimulation stimulates Kiss1 expression (mean ±SEM;
*p < 0.05).
(C) Representative IB of cultured mouse hepatocytes after treatment with PBS, glucagon, insulin, or INS plus GCGN. Glucagon stimulates kisspeptin; insulin
treatment has little effect on already low kisspeptin. Insulin counterregulates glucagon stimulation of kisspeptin.
(D) qRT-PCR ofKiss1 in liver tissue ofWTmice after in vivo ip treatment with vehicle (PBS) or glucagon. Glucagon treatment stimulatesKiss1 in liver (mean ±SEM;
*p < 0.05).
(E) Representative liver IB in WT mice after in vivo ip treatment with PBS or glucagon. Glucagon increases liver kisspeptin1 (mean ±SEM; *p < 0.05).
(legend continued on next page)
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GSIS in a dose-dependent fashion (Figure 1E).
To identify this PKA-regulated factor, we analyzed by micro-
array L-DPrkar1a and control mouse livers for differentially
expressed genes encoding secreted proteins. We identified a
single candidate transcript encoding kisspeptin1 (Kiss1) (Fig-
ure 1F) to be elevated in liver tissue of L-DPrkar1a mice (p <
1011; log2FC = 2.17). Quantitative RT-PCR (qRT-PCR) and im-
munoblots (IBs) of liver tissue confirmed increased hepatic kiss-
peptin1 production in L-DPrkar1a mice (Figure 1G). Conversely,
liver Kiss1 was reduced by 50% in D-glucose mice (Figure 1G).
Glucagon Stimulates Hepatic Kiss1 Expression via Gcgr
and cAMP-PKA-CREB Signaling
We next examined whether glucagon directly stimulates hepatic
kisspeptin1 production. Glucagon treatment (200 pg/ml) of
primary mouse hepatocytes stimulated within 2 hr Kiss1 expres-
sion and protein (Figures 2A–2C). As expected, the gluconeo-
genic gene Pck1, an internal control, was also stimulated
by glucagon (Figure 2A). Consistent with glucagon-activated
cAMP-PKA signaling, mouse hepatocytes treated for 2 hr with
the adenylyl cyclase activator forskolin (fsk) plus the phosphodi-
esterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) exhibited
increased Kiss1 expression (Figure 2B).
A luciferase reporter plasmid containing 1 kb of the mouse
Kiss1 promoter element transfected into mouse H2.35 hepa-
toma cells showed transcriptional activation in response to
glucagon or to fsk/IBMX treatment (Figure S2A). The mouse
Kiss1 promoter contains two putative functional cAMP response
element (CRE) half-sites (TGACT) (Zhang et al., 2005) located
at 127 and 758 bp upstream of the Kiss1 transcription start
site. Mutation of either of the CRE half-sites decreased the tran-
scriptional responses to glucagon or to fsk/IBMX, and combined
mutation of both CRE half-sites further decreased the responses
(Figure S2A).
In accordance with CREB mediating cAMP-stimulated Kiss1
transcription, cotransfection in H2.35 cells with constitutively
active CREB Y134F stimulated Kiss1 reporter activity as long
as CRE1 and CRE2 sites were intact, while dominant negative
CREB inhibitor A-CREB blocked reporter stimulation by fsk/
IBMX (Figures S2B and S2C). Consistent with these findings is
robust cAMP-PKA-CREB responsiveness of the human Kiss1
promoter, which contains a functional CRE half-site at 45 bp
proximal to the transcription start site (Zhang et al., 2005). Chro-
matin of mouse liver extracts using nonspecific versus CREB-(F) qRT-PCR of Kiss1 in liver of ad-lib-fed, O/N-fasted, and refed WT mice. F
(mean ±SEM; *p < 0.05).
(G) Liver IB from ad-lib-fed, O/N-fasted, and refed WT mice. Fasting stimulates l
(H) qRT-PCR of Kiss1 in liver of L-DGcgr mice after ip PBS or glucagon. Glucago
(I) (Top) Representative liver IB fromGcgrfl/fl and L-DGcgrmice. L-DGcgr lack GCG
or glucagon. Baseline kisspeptin1 is similar in Gcgrfl/fl and L-DGcgr mouse liver. G
(J) qRT-PCR of Kiss1 in liver of ad lib fed and O/N fasted L-DGcgr mice. O/N fas
(K) Representative liver IB from ad-lib-fed and O/N-fasted Gcgrfl/fl and L-DGcg
stimulates kisspeptin1 in Gcgr fl/fl but not in L-DGcgr liver.
(L) qRT-PCR of Kiss1 in liver of Insrfl/fl and L-DInsr mice. Liver Insr ablation does
(M) Representative liver IB of Insrfl/fl and L-DInsr mice. L-DInsr liver lacks insulin
(N) qRT-PCR of Kiss1 in liver of Insrfl/fl and L-DInsr mice after ip treatment with veh
L-DInsr liver (mean ±SEM; *p < 0.05).
(O)Representative liver IBof Insrfl/flandL-DInsrmiceafter ipPBSorglucagon.Gluca
Cspecific antiserum combined with qPCR of CRE half-site
sequences (in vivo chromatin immunoprecipitation), confirmed
in vivo CREB occupancy of both CRE half-sites within the
Kiss1 promoter (Figure S2D).
Intraperitoneal (ip) glucagon (16 mg/kg) but not PBS, treatment
in mice increased hepatic kisspeptin1 production 30 min after
injection (Figures 2D and 2E). Physiologic endogenous glucagon
secretion provoked by overnight fasting (Figure S2E) resulted in
increased hepatic kisspeptin1 production when compared to
ad-libitum-fed mice (Figures 2F and 2G). Fasted and subse-
quently refedmice exhibited a reduction in blood glucagon levels
(Figure S2D) and also of liver Kiss1 mRNA and kisspeptin1 pro-
tein (Figures 2F and 2G). Kiss1 transcript was also detectable
by qRT-PCR at low levels in spleen, kidney, skeletal muscle,
and epididymal fat tissue. In these tissues, Kiss1 expression
remained unchanged during fasting (data not shown), indicating
that the liver is the main site where Kiss1 expression is regulated
by metabolic cues.
To confirm the role of the liver glucagon receptor in mediating
in vivo effects of glucagon on hepatic kisspeptin1 production, we
generated floxed glucagon receptor (Gcgrfl/fl) mice (Figure S3A),
in which we conditionally ablated liver Gcgr by Adv-CRE delivery
(L-DGcgr mice) (Figure S3B). Adv-GFP injected Gcgrfl/fl mice
served as controls. Adv-CRE treatment did not ablate Gcgr in
islet, hypothalamus, and adpose tissue (Figure S3B). Deprivation
of hepatic glucagon signaling in L-DGcgr mice resulted in
reduced fasting glucose levels, improved GT, and unchanged
insulin tolerance (Figures S3C and 3D). L-DGcgr mice showed,
as compared to controls, slightly but not significantly reduced
liver kisspeptin1 expression (Figure 2H,I). Importantly, in
L-DGcgrmice, kisspeptin production did not change in response
to ip glucagon treatment or after overnight fasting (Figures 2J
and 2K). Plasma kisspeptin levels in Gcgrfl/fl and L-DGcgr mice
reflected respectively, changes in liver kisspeptin production in
response to glucagon treatment or fasting (Figures S2G and
S2H). Furthermore, L-DGcgr mice showed, as compared to
controls, significantly dampened liver CREB phosphorylation
and CREB occupancy of the Kiss1 promoter CRE half-sites in
response to glucagon treatment or to overnight fasting (Figures
S3E and S3F).
Glucagon and Insulin Counterregulate Liver Kisspeptin1
Expression
In the liver, insulin counteracts glucagon action on cAMP-CREB-
regulated genes (He et al., 2009). Accordingly, in vitro insulinasting stimulates liver Kiss1 expression; refeeding supresses elevated Kiss1
iver kisspeptin1.
n does to stimulate Kiss1 in L-DGcgr mice (mean ±SEM; *p < 0.05).
R. (Bottom) Liver IB fromGcgrfl/fl and L-DGcgrmice after ip treatment with PBS
lucagon treatment stimulates kisspeptin1 in Gcgrfl/fl but not in L-DGcgr mice.
t does not stimulate Kiss1 in L-DGcgr mouse liver (mean ±SEM; *p < 0.05).
r mice. Baseline kisspeptin1 is similar in Gcgrfl/fl and L-DGcgr livers. Fasting
not affect Kiss1 expression (mean ±SEM; *p < 0.05).
receptor immunoreactivity.
icle PBS or glucagon. Glucagon stimulates Kiss1 in Insrfl/flmice and more so in
gonstimulatesstronger liver kisspeptin1production inL-DInsr than in Insrfl/fl liver.
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Figure 3. In L-Dprkar1aMice LiverKiss1Knockdown Derepresses GSIS and Ameliorates Glucose Tolerance despite Continued Upregulated
Gluconeogenesis
(A) (Top) Liver kisspeptin1 IB, (bottom left) liver qRT-PCR of Kiss1mRNA, and (bottom right) plasma kisspeptin1 in L-Dprkar1a mice 3 days after Adv-scr or Adv-
Kiss1 shRNA treatment. Liver kisspeptin1 protein, Kiss1mRNA, and plasma kisspeptin1 are reduced after Kiss1 Kiss1 L-Dprkar1a mice (mean ±SEM; *p < 0.05).
(B) (Top) pCREB and total CREB IB. (Bottom) qRT-PCR of Ppargc1a and Pck1 in liver of L-Dprkar1a mice 3 days after Adv-scr shRNA or Adv-Kiss1 shRNA
treatment. CREB phosphorylation and total CREB protein are unaffected by Kiss1 knockdown in L-Dprkar1a liver. Ppargc1a and Pck1 mRNA levels are upre-
gulated in L-Dprkar1a as compared to prkar1afl/fl livers and are unaffected by liver Kiss1 knockdown in L-Dprkar1a mice (mean ±SEM; *p < 0.05).
(C) In vivo chromatin immunoprecipitation (ChIP) of CREB occupancy on CRE1 and CRE2 within the Kiss1 promoter in liver samples. CREB occupancy on Kiss1
CRE1 and CRE2 in L-Dprkar1a liver is increased as compared to prkar1afl/fl liver and unaffected by Kiss1 knockdown in L-Dprkar1amice (mean ±SEM; *p < 0.05).
(D) ipPCT in fed prkar1afl/fl and L-Dprkar1a mice 3 days after Adv-scr or Adv-Kiss1 shRNA treatment. Gluconeogensis activity is increased in L-Dprkar1a as
compared to prkar1afl/fl mice. Gluconeogenesis activity in L-Dprkar1a mice is unaffected by Kiss1 knockdown (mean ±SEM; *p < 0.05).
(legend continued on next page)
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basal Kiss1 expression and, as expected, also reduced Pck1
expression (Figure 2A). Insulin treatment dampened glucagon-
stimulated Kiss1 and Pck1 expression in mouse hepatocytes
(Figure 2A). Changes in Kiss1 expression were qualitatively
reflected in corresponding changes in kisspeptin1 protein levels
in response to glucagon and insulin treatment, respectively
(Figure 2C).
To verify that in vivo insulin effects on liver Kiss1 expression
are directly mediated by liver insulin receptors and to examine
whether isolated hepatic insulin resistance may modulate Kiss1
expression, we generated mice with liver-specific insulin recep-
tor deficiency by Adv-CRE treatment of floxed insulin receptor
(Insrfl/fl) mice (Bru¨ning et al., 1997) (L-DInsr mice; Figure 2L).
Importantly, Insr expression in islets, hypothalamus, adipose
tissue, and skeletal muscle was not different between Insrfl/fl
and L-DInsr mice (Figure S2F). Hepatic ablation of insulin recep-
tor by Adv-CRE in mice did not change liver Kiss1mRNA or pro-
tein levels (Figures 2M–2O). Conversely, glucagon treatment
of L-DInsr mice, as compared to Insrfl/fl mice, dramatically
increased liver Kiss1 transcript and kisspeptin protein (Figures
2N and 2O). Plasma kisspeptin1 levels in Insrfl/fl and L-DInsr
mice, respectively, reflected the changes in liver kisspeptin pro-
duction (Figure S2I).
Consistent with these observations of insulin counterregula-
tion of PKA-mediated Kiss1 stimulation, in vivo ip insulin
(1 IU/kg) administration in L-DPrkar1a mice to supplement rela-
tively deficient endogenous serum insulin concentrations and
to achieve blood glucose reduction, decreased hepatic Kiss1
mRNA and protein levels within 60 min (Figures S1I–S1K).
These findings indicate that—as is established for cAMP-
CREB-responsive gluconeogenic genes—insulin at sufficiently
high concentrations antagonizes glucagon stimulation of Kiss1
expression. Further, in vivo disruption of the hepatic insulin
receptor (i.e., liver insulin resistance) alone does not derepress
liver kisspeptin1 production absent additional glucagon
signaling. These findings also indicate that the liver is the
predominant source of circulating kisspeptin1, which is subject
to hormonal regulation.
Kisspeptin1 Knockdown in L-DPrkar1a Mice
Ameliorates GSIS despite Continued Gluconeogenesis
To verify that in L-DPrkar1a mice hepatic kisspeptin1 is directly
linked to impaired GSIS, we knocked down hepatic kisspeptin1
in L-DPrkar1a mice by administering adenovirus expressing
Kiss1-specific shRNA (Adv-Kiss1 shRNA) or a control scrambled
shRNA adenovirus (Adv-scr shRNA). Within 3 days of treatment,
Adv-Kiss1-shRNA-treated mice showed reduced hepatic Kiss1
mRNA and plasma kisspeptin (Figure 3A). In contrast, gluconeo-
genesis, as reflected by mRNA of the gluconeogenic genes(E) ipITT in L-Dprkar1a mice 3 days after treatment with Adv-scr or Adv-Kiss1 s
knockdown (mean ±SEM; *p < 0.05).
(F) ipGTT in L-Dprkar1a mice 3 days after treatment with Adv-scr or Adv-Kiss1 sh
to controls (mean ±SEM; *p < 0.05).
(G) Serum insulin during ipGTT in L-Dprkar1a mice 3 days after treatment with A
Kiss1 knockdown as compared to controls (mean ±SEM; *p < 0.05).
(H) Body weight in L-Dprkar1amice 3 days after treatment with Adv-scr or Adv-Kis
(I) Caloric intake in L-Dprkar1a mice during 3 days after treatment with Adv-scr o
knockdown.
C(Figure 3B) as well as functional conversion of ip administered
gluconeogenic precursor pyruvate to glucose in the fed (nonfast-
ing) state (ip pyruvate conversion test) was similar between
Adv-Kiss1 shRNA and control Adv-scr-shRNA-treated
L-DPrkar1a mice and also significantly increased as compared
to WT mice (Figure 3D). Furthermore, liver CREB phosphory-
lation and CREB occupancy of the endogenous Kiss1 promoter
was similar in Adv-scr shRNA and Adv-Kiss1-shRNA-treated
L-DPrkar1a mice (Figures 3B and 3C), indicating that PKA
signaling per se is not differentially affected by Kiss1-specific
versus scr shRNA treatment.
Despite ongoing upregulated hepatic gluconeogenesis
(Figures 3B–3D), Kiss1 knockdown in L-DPrkar1a mice
increased in vivo GSIS and improved GT (Figures 3F and 3G).
ipITT (Figure 3E), food intake, and body weight (Figures 3H
and 3I) were similar in Adv-Kiss1 and Adv-scr-shRNA-treated
L-DPrkar1a mice, excluding differences in insulin sensitivity or
caloric intake in Adv-Kiss1 versus Adv-scr-shRNA-treated
animals as mechanisms, respectively, for improved GT or for a
compensatory increase in insulin secretion in the face of altered
insulin resistance.
Kisspeptin Impairs GSIS at Nanomolar Concentrations
via Interaction with its Receptor Kiss1R on Pancreatic b
cells
The Kiss1R shares 82% homology between humans and mouse
(Ohtaki et al., 2001). IB confirmed Kiss1R expression in protein
extracts of mouse islets, in INS1 and Min6 insulinoma cells,
and in human islets (Figure 4A). Immunohistochemistry com-
bined with confocal imaging of mouse pancreas localized
Kiss1R expression to insulin-producing pancreatic b cells but
not to a cells (Figure 4B), indicating that kisspeptin1-Kiss1R
signaling likely occurs directly on b cells.
To specifically investigate the functional role of Kiss1R on b
cells in mediating kisspeptin1 action on GSIS, we generated
mice lacking pancreatic Kiss1R by interbreeding PDX1-CRE
(Lammert et al., 2001) and floxed Kiss1R (Kiss1rfl/fl) (Novaira
et al., 2013) mice to yield Panc-DKiss1Rmice (Figure S4A). Anal-
ysis of pancreata revealed similar morphometric parameters and
insulin content in control and Panc-DKiss1R mice (Figure S4B).
Panc-DKiss1R mice, as compared to Kiss1rfl/fl controls, ex-
hibited similar plasma glucagon levels (Figure S4B), slightly
elevated fasting serum insulin levels, similar glucose levels,
and similar GT during ipGTT (Figure 4C). In contrast, treatment
with K54 (10 nmol ip) suppressed GSIS in Kiss1rfl/fl mice but
did not affect GSIS in Panc-DKiss1R mice (Figure 4D). Together
with the confocal microscopic observation, which localized
Kiss1R within the endocrine pancreas restricted to b cells (Fig-
ure 4B), these results indicate that kisspeptin1 suppresses
GSIS by direct action via its receptor on b cells.hRNA. Peripheral insulin sensitivity in L-Dprkar1a mice is unaffected by Kiss1
RNA. L-Dprkar1a mice with Kiss1 knockdown show improved GT as compared
dv-scr or Adv-Kiss1 shRNA. GSIS is augmented in L-Dprkar1a mice after liver
s1 shRNA. Body weight in L-Dprkar1amice is unaffected byKiss1 knockdown.
r Adv-Kiss1 shRNA. Caloric intake in L-Dprkar1a mice is unaffected by Kiss1
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Figure 4. Kisspeptin1 at Nanomolar Concentrations Inhibits GSIS in a Kiss1R-Dependent Manner
(A) Representative IB for Kiss1R mouse brain, HEK293T cells, mouse islets, INS1 rat insulinoma cells, Min6 mouse insulinoma cells, and human islets. Mouse
brain, mouse islets, insulinoma cells, and human islets express Kiss1R. HEK293T cells do not expess Kiss1R.
(B) (Left) Immunohistochemistry for insulin, glucagon, and Kiss1R in pancreas from Kiss1Rfl/fl mice. Kiss1R immunoreactivity colocalizes with insulin-positive b
cells but not with glucagon-positive a cells. Showing 203magnification. Pseudocoloring is as follows: red for glucagon, green for insulin, yellow for Kiss1R, and
blue for nucleus counterstain with DAPI (left bottom) inset of previous image at 403 magnification. (Right top) Immunohistochemistry for insulin, glucagon,
and Kiss1R in pancreas fromPanc-DKiss1Rmice. Kiss1R immunoreactivity is lacking in Panc-DKiss1R islet. (Right bottom) Representative islet IB from Kiss1Rfl/fl
and Panc-DKiss1R mice. Kiss1R is absent in Panc-DKiss1R islets.
(C) ipGTT in Kiss1Rfl/fl and Panc-DKiss1R mice during ip coinjection of PBS and glucose. (Top) GT is similar in Kiss1Rfl/fl and Panc-DKiss1R mice. (Bottom)
Baseline fasting glucose is slightly elevated in Panc-DKiss1R mice as compared to Kiss1Rfl/fl littermates. In vivo GSIS is similar in Kiss1Rfl/fl and Panc-DKiss1R
mice (mean ±SEM; *p < 0.05).
(D) ipGTT in Kiss1Rfl/fl and Panc-DKiss1R mice during ip coinjection of 10 nM K54 and glucose. K54 impairs GT (top) and GSIS (bottom) in Kiss1Rfl/fl but not in
Panc-DKiss1R mice (mean ±SEM; *p < 0.05).
(E) (Top) Dose response curve of K54 and K10 inhibition of GSIS from WT mouse islets during static at 10 or 20 mM glucose. Both K54 and K10 inhibit GSIS in a
dose-dependent manner from 0 to 100 nM at both 10 and 20 mM glucose; (bottom) GSIS from Kiss1R fl/fl and Panc-DKiss1R islets treated with PBS K10 or K54.
K10 or K54 (both 10 nM) inhibit GSIS from Kiss1R fl/fl but not from Panc-DKiss1R islets.
(F) cAMP synthesis andGSIS in response to K54 and to incretin analog exendin-4 (E4) in Kiss1R fl/fl and Panc-DKiss1R islets. (Top) K54 impairs cAMP synthesis in
Kiss1Rfl/fl but not in Panc-DKiss1R islets. E4 stimulates cAMP synthesis similarly in both Kiss1Rfl/fl and in Panc-DKiss1R islets. K10 reduces E4-stimulated cAMP
levels inKiss1Rfl/fl but not in Panc-DKiss1R islets. (Bottom) During static incubation of mouse islets, K54 impairs GSIS and also E4 potentiation of GSIS from islets
in a dose-dependent manner (mean ±SEM; *p < 0.05).
(G) Islet perifusion assay in WT islets in response to K54 and to E4. (Top) K54 impairs both first and second phasea of GSIS and (bottom) E4-potentiated first and
second phase GSIS; end of perifusion shows similar insulin release upon KCL induced depolarization (mean ±SEM; *p < 0.05).
(H) Area under the curve (AUC) of (top) first and (bottom) second phase GSIS from WT mouse islets treated with PBS, K54, E4, or K54+E4. K54 inhibits both first
and second phases of GSIS and E4 potentiated GSIS (mean ±SEM; *p < 0.05).
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and at concentrations as low as 0.1 nM from Kiss1Rfl/fl mouse
islets that were cultured in serum-free media containing either
10 or 20 mM glucose (Figure 4E, top), whereas Panc-DKiss1R
mice were impervious to K54-mediated GSIS suppression
(Figure 4E, bottom). K10 tested at concentrations equimolar to
K54 was equally effective in suppressing GSIS in vivo and
in vitro (not shown).
Kisspeptin at different concentrations has been reported to
either suppress or stimulate GSIS. Kisspeptin isoforms at nM
concentrations suppress GSIS (Silvestre et al., 2008; Vikman
and Ahre´n, 2009). In contrast, GSIS stimulation has been re-
ported only at kisspeptin concentrations in the range of 103 nM
(i.e., 1 mM) (Bowe et al., 2012; Hauge-Evans et al., 2006), which
is unusually high for a hormone.
To examine the effects of such high kisspeptin concentrations
on GSIS, we treated islets with 103 nM (equals 1 mM) K54 or K10
and found GSIS stimulation from both Kiss1Rfl/fl and Panc-
DKiss1R islets (Figure S4C). These findings, using selective
genetic Kiss1R ablation suggest that kisspeptin at very high
concentrations may stimulate GSIS in a Kiss1R-independent
mechanism raising the possibility of off-target effects on GSIS
of supraphysiologic kisspeptin concentrations.
Kisspeptin Suppresses Islet cAMP Synthesis and
Antagonizes Incretin Hormone Glucagon-Like peptide-1
Receptor-Mediated GSIS Potentiation
GSIS is potentiated by increased cAMP concentrations in b cells
(Drucker, 2006). Kiss1R belongs to Class I/A of G protein
coupled receptors and shares structural similarities with the
galanin receptor, activation of which suppresses cAMP synthe-
sis in b cells (Lee et al., 1999; Tang et al., 2012). We reasoned
that kisspeptin1 may also modulate b cell cAMP levels. WT
mouse islets kept at 10 mM glucose and treated with K54
(10 nM) contained lower cAMP concentrations as compared to
PBS-treated islets (Figure 4F). K54 also impaired islet cAMP
production in response to the long-acting incretin hormone
analog exendin-4 (E4) (Figure 4F)—a widely used antidiabetic
agent that binds and activates on b cells the receptor for the
incretin hormone glucagon-like peptide-1 (GLP-1) and potenti-
ates GSIS by stimulating b cell cAMP synthesis (Drucker,
2006). Conversely, Panc-DKiss1R islets exhibited slightly
increased baseline and E4-induced cAMP concentrations,
whichwere not affected by K54 treatment (Figure 4F). Consistent
with an antagonism between K54 and E4, respectively, on b cell
function, K54 dose-dependently suppressed E4-potentiated
GSIS from mouse islets cultured at 10 mM glucose (Figure 4F,
bottom). Perifusion studies of isolated mouse islets revealed
that both K54 and K10 suppressed first (0–10 min after glucose
stimulation) and second phases of GSIS (Figures 4G and 4H) as
well as E4-potentiated GSIS (Figures 4G and 4H). KCl-induced
(30 mM) depolarization of Kiss1Rfl/fl and Panc-DKiss1R islets
after perifusion stimulated release of equal amounts of insulin,
indicating that insulin exocytosis mechanisms distal to the regu-
latory b cell ATP-dependent potassium channel (KATP channel)
are not impaired in Panc-DKiss1R islets (Figure 4G).
These observations indicate that kisspeptin1 reduces b cell
cAMP production and renders b cells resistant to incretin action
on cAMP synthesis and GSIS potentiation.CMouseModels of Impaired GT and DM Exhibit Increased
Liver Kisspeptin1 Production
We next examined the relevance of glucagon and kisspeptin1
production in the context of DM. Mice receiving for 8 weeks a
HFD developed glucose intolerance and insulin resistance as
compared to standard diet (SD)-fed controls (Figures S5A and
S5B) and, importantly, exhibited increased plasma glucagon
levels in the fed state (Figure S5C) and an increase in liver
Kiss1 expression (Figure 5A).
In the hypothalamus, Kiss1 expression is modulated by leptin
signaling (Smith et al., 2006). Furthermore, leptin inhibits GSIS
via its receptor on b cells (Kieffer et al., 1997). Therefore, to eluci-
date the relevance of hyperglucagonemia on liver Kiss1 and
GSIS independent of leptin effects, we also examined mice
homozygous for the inactivating leptin receptor db mutation
(Leprdb/db mice).
Leprdb/db as compared toWTmice exhibited hyperglucagone-
mia in the fed state (Figure S5D) and significantly increased liver
Kiss1 expression (Figure 5A). Both plasma glucagon and liver
Kiss1 mRNA levels were greater in magnitude in Leprdb/db as
compared to those found in HFD mice. Accordingly, kisspeptin1
immunoreactivity was detectable at low levels in liver of SDmice
and was increased both in HFD and in Leprdb/db liver tissue (Fig-
ure 5A). Both HFD-fed mice and Leprdb/db liver tissue showed
higher CREB phosphorylation (Figure S5F) and in vivo CREB
occupancy on both CRE half-sites within the Kiss1 promoter
(Figure S5G).
Plasma from HFD-fed and diabetic Leprdb/db mice—as
compared to SD fed WT mice—exhibited higher kisspeptin1
concentrations as determined by ELISA (Figure 5B). Kiss1Rfl/fl
islets cultured in serum-free media conditioned with plasma
from HFD or from Leprdb/db mice exhibited impaired GSIS. In
contrast, Panc-DKiss1R islets resistedGSIS inhibition by plasma
of HFD or Leprdb/db mice. GSIS suppression from WT islets
cultured in serum-free media conditioned with HFD or Leprdb/db
plasma (Figure 5C)—when compared with GSIS suppression by
synthetic K54 (Figure 4H)—indicated that the functional plasma
kisspeptin concentrations in HFD and Leprdb/db mice to be
equivalent to 0.5–1 nM and 7–10 nM of K10, respectively.
We further examined the relevance of liver kisspeptin in
the context of human T2DM. Kisspeptin1 immunoreactivity
was detectable at variable intensity by immunoblot of liver
samples from humans with T2DM but not from nondiabetic
humans (Figure 5D). Accordingly, circulating kisspeptin1 immu-
noreactivity was increased in serum from humans with T2DM,
as compared to nondiabetic individuals (Figure 5E). Media
conditioned with serum from T2DM, but not from nondiabetic,
individuals suppressed GSIS from Kiss1Rfl/fl but not from
Panc-DKiss1R islets (Figure 5F). These observations indicate
that—akin to rodent models of DM—in human T2DM liver kiss-
peptin1 expression is increased and that circulating kisspeptin
suppresses GSIS.
Liver Kiss1 Upregulation is Linked to
Hyperglucagonemia in DM
We determined whether hyperglucagonemia is linked to liver
kisspeptin production in HFD and Leprdb/db mice by adminis-
tering a single dose of the selective Gcgr antagonist (GAI) or an
inactive analog (GAC) (Qureshi et al., 2004) 60 min beforeell Metabolism 19, 667–681, April 1, 2014 ª2014 Elsevier Inc. 675
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Figure 5. Liver Kisspeptin1 Expression and Plasma Kisspeptin Levels Are Elevated in Mouse Models of DM and in Humans with T2DM
(A) (Top) qRT-PCR for Kiss1 in liver tissue and (bottom) liver IB for kisspeptin1 in SD, HFD-fed, and Leprdb/dbmice. Both Kiss1mRNA and kisspepetin1 protein are
increased in HFD-fed mice and found at higher levels in db/db mouse livers (mean ±SEM; *p < 0.05).
(B) Plasma kisspeptin1 in SD, HFD-fed, and Leprdb/dbmice. Plasma kisspeptin1 is increased in (left) HFD fed and (right) in Leprdb/dbmice as compared to SD fed
littermates (mean ±SEM; *p < 0.05).
(C) GSIS from cultured (left) Kiss1Rfl/fl and (right) Panc-DKiss1R mouse islets in media conditioned with plasma from HFD fed and Leprdb/db mice. GSIS from
Kiss1Rfl/fl is suppressed during culture in media conditioned with HFD fed or db/db plasma at 1:10 dilution but not at 1:100 dilution. GSIS from Panc-DKiss1R
islets is unaffected by media conditioned with plasma of HFD fed or Leprdb/db mice (mean ±SEM; *p < 0.05).
(D) Representative liver IB for kisppeptin1 in humans without DM and humans with T2DM. Humans with T2DM exhibit varying degrees of kisspeptin immuno-
reactivity in liver tissue.
(E) Plasma kisspeptin1 in humans without DM and with T2DM. Plasma kisspeptin1 levels are elevated in humans with T2DM as compared to humans without
diabetes (mean ±SEM; *p < 0.05).
(F) GSIS from cultured (left) Kiss1Rfl/fl and (right) Panc-DKiss1R mouse islets in media conditioned with plasma from humans with T2DM and without DM. GSIS
from Kiss1Rfl/fl but not from Panc-DKiss1R islets is suppressed during culture in media conditioned with T2DM plasma (mean ±SEM; *p < 0.05).
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6F–6M) mice exhibited improved basal glycemia as well as GT.
GAI treatment led to a reduction in liver gluconeogenic gene (Fig-
ures 6C–6I) and in Kiss1 expression (Figures 6D–6J) and to
corresponding reductions in liver pCREB (Figures 6B–6H) and
CREB occupancy of CRE 1 and 2 in the Kiss1 promoter (Figures
6E–6K). Circulating plasma glucagon levels remained un-
changed after GAI or GAC treatment in both HFD fed (Figure 6A)
and Leprdb/db mice (Figure 6G), respectively.
Thus, in the context of glucose intolerance and DM, hyper-
glucagonemia significantly contributes to hepatic kisspeptin1
production. Further, as demonstrated in Leprdb/db mice, hepatic
Kiss1 regulation occurs independently of leptin.
Liver Kisspeptin1 Knockdown in Diabetic Mice
Ameliorates GSIS and GT
We next examined the contribution in DM of hepatic kisspeptin1
toward impaired GSIS by liver-selective shRNA-mediated Kiss1676 Cell Metabolism 19, 667–681, April 1, 2014 ª2014 Elsevier Inc.knockdown. Adv-Kiss1 but not -scr shRNA treatment in HFD or
Leprdb/db mice (5–6 weeks of age), respectively, reduced within
3 days liver kisseptin1 production (Figures 7A–7H) and Kiss1
mRNA (Figures 7B–7I) as well as plasma kisspeptin1 (Figures
7C–7J). Plasma glucagon (Figures 7D–7K), liver pCREB (Fig-
ure 7A,H), and liver CREB occupancy on Kiss1 promoter CRE
sites (Figures S6A–S6C) remained similar in Adv-Kiss1 and
Adv-scr-shRNA-treated littermates. Liver kisspeptin1 knock-
down in both HFD and Leprdb/db mice resulted in improved
in vivo GT (Figures 7E–7M) and increased GSIS (Figures 7F–
7N). Caloric intake (Figures 7E–7K), body weight (Figures S6B–
S6D), and insulin tolerance (Figures 7G–7O) were not different
in Adv-Kiss1 and Adv-scr-shRNA-treated counterparts, ruling
out changes in insulin sensitivity after Kiss1 knockdown as a
mechanism for improvements in GSIS and GT.
These observations indicate that in DM, liver kisspeptin1
negatively impacts GSIS, which can be derepressed by inhibiting
hepatic kisspeptin1 production.
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Secretion and GT in HFD Mice
To directly assess the relevance of kisspeptin-Kiss1R signaling
on GSIS in the context of DM, we examined the effects of condi-
tional pancreas Kiss1R ablation in HFD fed mice. Kiss1Rfl/fl and
Panc-DKiss1R mice, placed on a HFD for 8 weeks, exhibited
similar weight gain (Figure S7). Liver kisspeptin1 immunoreac-
tivity, plasma kisspeptin, and glucagon levels were similar in
HFD mice independent of pancreas Kiss1R status (Figure S7).
Importantly, Panc-DKiss1R showed, as compared to Kiss1Rfl/fl
littermates, slightly lower fasting blood glucose and improved
GT (Figure S7). HFD-fed Panc-DKiss1R showed, relative to
controls, both increased fasting insulin and in vivo GSIS. No
differences were found in insulin tolerance, islet, b cell or a cell
mass, or pancreas insulin content between Panc-DKiss1R and
Kiss1Rfl/fl littermates (Figure S7), excluding changes in peripheral
insulin action or b cell mass to account for improved GSIS and
GT in HFD-fed Panc-DKiss1R mice.
DISCUSSION
The present findings using genetically defined mouse models
suggest a trihormonal regulatory circuit between pancreatic a
cells, hepatocytes, and b cells and assign kisspeptin1 an un-
expected role in liver to islet endocrine signaling. In addition,
the findings indicate in T2DM a sequential link between hyper-
glucagonemia and impaired b cell function via liver-derived
kisspeptin1.
Hyperglucagonemia, which occurs early during development
of T2DM, upregulates kisspeptin1 production by the liver (Fig-
ure 2). Kisspeptin1 in turn functions as a hormone to suppress
GSIS (Figure 4). Thus, in T2DM the b cell is exposed to two coun-
teracting stimuli elicited by glucagon action on the liver.
Glucagon-induced HGP and hyperglycemia stimulate, whereas
kisspeptin1 production inhibits, GSIS.
The physiologic relevance of opposing actions of hepatic
cAMP-CREB signaling on b cell function remains to be fully
explored. Teleological considerations render plausible a survival
mechanism in that hepatic cAMP-CREB-induced kisspeptin1
serves as a (among other mechanisms) safeguard against insulin
secretion and hypoglycemia during fight and flight reactions,
should these occur during and interrupt prandial nutrient absorp-
tion—when insulin secretion otherwise would be elevated. To
this end, it is likely that epinephrine, another fight and flight
mediator, which activates liver cAMP signaling (Sherline et al.,
1972), may also participate in liver Kiss1 regulation.
It is important to note that our studies using genetically defined
Kiss1R-deficient islets reveal that kisspeptin applied at supra-
physiologic doses in the micromolar range stimulates GSIS,
likely due to effects which are not mediated by the bona-fide
Kiss1R (Figure S4C). This observation of Kiss1R-independent
effects at high doses of kisspeptin, which are unusually high
for a hormone, may in part explain the contradictory observa-
tions on GSIS between physiologic and supraphysiologic kiss-
peptin1 concentrations (Bowe et al., 2012; Hauge-Evans et al.,
2006; Silvestre et al., 2008; Vikman and Ahre´n, 2009). Our
studies suggest that Kiss1R signaling in b cells suppresses
cAMP and inhibits GSIS. An intravenous bolus K10 in the
nonhuman primate Macaca mulatta is reported to stimulateCGSIS, albeit circulating kisspeptin concentrations were not
measured in that study (Wahab et al., 2011). Based on the
studies herein, humans with T2DM exhibit increased liver kiss-
peptin1 immunoreactivity and increased circulating kisspeptin,
and their plasma suppresses GSIS from mouse islets in a
Kiss1R-dependent manner (Figures 3 and 4). Future studies on
the interplay between glucagon and kisspeptin1 in humans
will need to carefully examine the dose response of kisspeptin1
on GSIS combined with reliable measurements of circulating
functional kisspeptin1 isoforms.
Our observations further suggest that in T2DM GSIS is insuffi-
cient to overcome the coexisting inhibition on b cells exerted
by kisspeptin1. This mechanism results in inadequate insulin
secretion to meet metabolic demands and aggravates b cell
dysfunction and hyperglycemia. Clinical observations indicate
that in T2DM, although incretin GLP-1 is normally secreted,
endogenous GLP-1 is insufficient to achieve physiologic GSIS
potentiation. Furthermore, treatment with dipeptidyl-peptidase
IV inhibitors, which inhibit GLP-1 degradation and increase
endogenous GLP-1 concentrations by 2-fold, or treatment with
long-acting GLP-1 analog E4 restore b cell function in T2DM.
These observations have led to the concept of reduced GLP-1
sensitivity of b cells in T2DM (Meier and Nauck, 2008). Antago-
nism by K54 on E4-induced GSIS potentiation (Figures 4E and
4F) suggests that increased circulating kisspeptin1 levels in
T2DMmay at least in part contribute to the diminished response
to endogenous GLP-1 in T2DM subjects.
Thus, our findings uncover the liver as a site of regulated kiss-
peptin production and provide mechanistic and causal under-
pinnings for the following common observations made in clinical
T2DM: (a) relative hyperglucagonemia, (b) insufficient insulin
secretion to regulate glycemia, and (c) diminished response to
endogenously secreted GLP-1 and restoration of b cell function
by pharmacologic GLP-1 receptor agonism.
In a broader context, neutralizing circulating kisspeptin1 or
antagonism of Kiss1R on b cells are appealing avenues to
augment GSIS and improve glucose homeostasis in T2DM. In
this regard, Kiss1R antagonists, which would not cross the
blood-brain barrier and interfere with hypothalamic reproductive
functions of kisspeptin1, would be particularly advantageous.
Another important aspect is that plasma kisspeptin1 activity
may serve as a biomarker to identify T2DM patients who would
benefit most from aggressive b-cell-targeted therapy.
EXPERIMENTAL PROCEDURES
Animal Studies
Animal studies were approved by the local Institutional Animal use and Care
Committee and were performed in 6- to 8-week-old C57Bl/6 male mice.
Leprdb/db (Leprdb/db; B6.BKS(D)-leprdb/J) mice were from Jackson Labora-
tories. Gcgrfl/fl were generated by homologous recombination technology
(Supplemental Experimental Procedures). Intravenous glucose infusions
were performed as described (Alonso et al., 2007). Genotyping PCR primers
and dynamic physiologic testing details are provided in Supplemental Experi-
emental Procedures.
Adenovirus Injection Studies
Adenovirus (Adv-CRE and Adv-GFP, University of Iowa) were injected into tail
vein (109 plaque forming units/mouse in 13PBS). Adenovirus expressing
shRNA under U6 promoter was generated (Life Technologies) to target the
following mouse Kiss1 sequence: GCTCTCTCTCTTTGACCTAGG.ell Metabolism 19, 667–681, April 1, 2014 ª2014 Elsevier Inc. 677
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Figure 6. Hyperlucagonemia Is Linked to Liver Kisspeptin1 Production in HFD Fed and Leprdb/db Mice
(A–F) HFD-fed mice.
(G–L) Leprdb/db mice.
(A and G) Plasma glucagon levels in the fed state 60 min after treatment with GAI or GAC. Plasma glucagon levels remain unchanged after GAI or GAC treament.
(BandH)Representative liver IB forpCREB, totalCREBandkisspeptin1 inGAIandGACtreatedmice.Phospho-CREBis reduced inmice treatedwithGAIbutnotGAC.
(C and I) qRT-PCR of indicated genes of the gluconeogenic program in livers of GAI- or GAC-treated mice. GAI but not GAC treatment downregulates Pparg1a,
Src1, G6P, and Pck1 mRNA (mean ±SEM; *p < 0.05).
(legend continued on next page)
Cell Metabolism
An Endocrine Circuit of Liver to Islet Crosstalk
678 Cell Metabolism 19, 667–681, April 1, 2014 ª2014 Elsevier Inc.
* *
Adv scr
shRNA
Adv Kiss1
shRNA
m
R
N
A 
le
ve
l
re
la
tiv
e 
to
A
dv
 s
cr
 c
on
tr
ol
Kiss1
0
1.0
0.5
1.5
pl
as
m
a 
ki
ss
pe
pt
in
 (n
g/
m
l)
kisspeptin
0
100
50
150
*
pl
as
m
a 
gl
uc
os
e 
(m
g/
dl
) 600
100
200
300
400
*
* *
*
0 30 60 90 120
0 10 20 30 40 50 60
se
ru
m
 in
su
lin
 (n
g/
m
l)
25
5
10
15
20
*
*
*
0
500
*
0
HFD +
Adv scr shRNA (n=3)
HFD +
Adv Kiss1 shRNA (n=3)
m
R
N
A 
le
ve
l
re
la
tiv
e 
to
A
dv
 s
cr
 c
on
tr
ol
Kiss1
0
1.0
0.5
1.5
*
pl
as
m
a 
ki
ss
pe
pt
in
 (n
g/
m
l)
kisspeptin
0
100
50
150
*
pl
as
m
a 
gl
uc
os
e 
(m
g/
dl
) 600
100
200
300
400
* *
0 30 60 90 120
0
500
*
0 10 20 30 40 50 60
se
ru
m
 in
su
lin
 (p
g/
m
l)
500
100
200
300
400
* *
0
Lepr db/db miceHFD fed mice
0 10 20 30 40 50 60
pl
as
m
a 
gl
uc
os
e 
(m
g/
dl
) 250
50
100
150
200
0
time after insulin ip (min)
0 10 20 30 40 50 60
pl
as
m
a 
gl
uc
os
e 
(m
g/
dl
)
time after insulin ip (min)
600
100
200
300
400
0
500
pl
as
m
a 
gl
uc
ag
on
 (p
g/
m
l) 150
0
100
50
glucagon
NS
*
300
pl
as
m
a 
gl
uc
ag
on
 (p
g/
m
l) NS
0
100
200
glucagon
Adv scr
shRNA
Adv Kiss1
shRNA
kisspeptin
actin
P-CREB
CREB
kisspeptin
actin
P-CREB
CREB
ca
lo
ric
 in
ta
ke
 (k
ca
l/3
d) 10
0
5
caloric intake
NS NS
ca
lo
ric
 in
ta
ke
 (k
ca
l/3
d) 40
20
caloric intake
0
30
10
A
B C
Lepr db/db +
Adv Kiss1 shRNA (n=3)
Lepr db/db +
Adv scr shRNA (n=3)
D E
F
G
H
I
J K
L M
N
O
P
Lepr db/db +
Adv Kiss1 shRNA (n=3)
Lepr db/db +
Adv scr shRNA (n=3)
Lepr db/db +
Adv Kiss1 shRNA (n=3)
Lepr db/db +
Adv scr shRNA (n=3)
Lepr db/db +
Adv Kiss1 shRNA (n=3)
Lepr db/db +
Adv scr shRNA (n=3)
HFD +
Adv scr shRNA
(n=3)
HFD +
Adv Kiss1 shRNA
(n=3)
HFD +
Adv scr shRNA (n=3)
HFD +
Adv Kiss1 shRNA (n=3)
HFD +
Adv scr shRNA (n=3)
HFD +
Adv Kiss1 shRNA (n=3)
time after glucose ip (min) time after glucose ip (min)
time after glucose ip (min) time after glucose ip (min)
Figure 7. Kiss1 shRNA Knockdown In Vivo in Livers of in HFD and Leprdb/db Mice Derepresses GSIS and Glucose Tolerance
(A–H) HFD mice.
(I–P) Leprdb/db mice.
(A and I) Representative liver IB of pCREB, total CREB, and kisspeptin1 3 days after treatment with Adv-scr or Adv-Kiss1 shRNA. Liver pCREB is not affected, and
liver kisspeptin1 protein is reduced by Kiss1 knockdown.
(B and J) qRT-PCR of Kiss1 in livers 3 days after treatment with Adv-scr or Adv-Kiss1 shRNA. Adv-Kiss1 shRNA downregulates liver Kiss1 mRNA levels as
compared to Adv-scr shRNA treatment (mean ±SEM; *p < 0.05).
(C and K) Plasma kisspeptin1 levels 3 days after treatment with Adv-scr or Adv-Kiss1 shRNA. Liver Kiss1 knockdown reduces plasma kisspeptin1 (mean ±SEM;
*p < 0.05).
(D and L) Plasma glucagon levels 3 days after treatment with Adv-scr or Adv-Kiss1 shRNA. Liver Kiss1 knockdown does not change plasma glucagon levels
(mean ±SEM).
(E and M) Caloric intake in during 3 days after treatment with Adv-scr or Adv-Kiss1 shRNA. Caloric intake is unaffected by Kiss1 knockdown (mean ±SEM).
(F and N) ipGTT 3 days after treatment with Adv-scr or Adv-Kiss1 shRNA. GT is improved after Kiss1 knockdown (mean ±SEM; *p < 0.05).
(G and O) GSIS during ipGTT 3 days after treatment with Adv-scr or Adv-Kiss1 shRNA. GSIS is improved after Kiss1 knockdown (mean ±SEM; *p < 0.05).
(H and P) ipITT 3 days after treatment with Adv-scr or Adv-Kiss1 shRNA. Insulin tolerance is not different after Kiss1 knockdown.
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An Endocrine Circuit of Liver to Islet CrosstalkImmunofluorescence Histology and Islet Morphometry
Pancreas immunofluorescence histology and morphometry and pancreas
insulin content measurment were conducted as described (Song et al.,
2011). Confocal imaging was performed on a Zeiss Axoivert. Antibodies are
provided in Supplemental Experiemental Procedures.
Isolated Islet Studies
Islet isolation was performed by collagenase digestion, gradient centrifuga-
tion, and three rounds of microscope-assisted manual picking of islets. Static
incubation studies were conducted as previously described with 20 hand-(D and J) qRT-PCR of Kiss1 in livers of GAI- and GAC-treated mice. GAI but not
(E and K) In vivo ChIP of CREB occupancy on (left) CRE1 and (right) CRE2 half-s
Leprdb/db mice. GAI reduces CREB occupancy on Kiss1 CRE1 and CRE2 to leve
(F and L) ipGTT in GAI- or GAC-treated mice. GAI treatment improves GT as com
Cpicked, equal-sized islets were studied in each group (Song et al., 2011). After
overnight culture (37C, 5% CO2, and 95% O2 in humid chamber) of isolated
islets in RPMI 1640 (Mediatech) containing 5 mM glucose, 1% each Na-Pyru-
vate, HEPES, Penicillin/Streptomycin, and 0.2% BSA, islets were switched to
either 10 or 20 mM glucose containing RPMI 1640. Where indicated, Kisspep-
tin-10 (0–100 nM, and 1 mM), E4 (10 nM), or vehicle (PBS) was added. After
30 min incubation glucose concentrations, supernatant was taken for insulin
measurements and pelleted islets were taken in acid ethanol (0.18M HCl in
70% ethanol) for insulin measurements in islets (ELISA, Alpco). Islet protein
concentration was measured using the BCA method (Thermo Fisher). DoseGAC treatment downregulates liver Kiss1 mRNA (mean ±SEM; *p < 0.05).
ites of the Kiss1 promoter in livers of GAI- or GAC-treated SD mice, HFD and
ls similar to those in control mice (mean ±SEM; *p < 0.05).
pared to GAC treatment (mean ±SEM; *p < 0.05).
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An Endocrine Circuit of Liver to Islet Crosstalkresponse curves of GSIS inhibition by Kisspeptin-54 or Kisspeptin-10
(0–100 nM) to serve as a functional bioassay for plasma kisspeptin1 activity
performed at six separate times provided intra-assay and interassay coeffi-
cient of variations of 7.3% and 9.2%, respectively.
IBs
IBs were performed as described (Song et al., 2011) in at least three different
separately obtained experimental samples. Luminescence images of repre-
sentative IBs are shown. Corresponding Actin IB show protein loading control.
Human Samples
The Institutional Review Board at Johns Hopkins University approved studies
of deidentified human samples. Human tissue and serum samples were
obtained from National Disease Research Interchange (NDRI) and Origene. In-
formation on samples is provided in Supplemental Experiemental Procedures.
Immunoassays
Kisspeptin1 ELISA for mouse (USCN Life Sciences) and human (Phoenix) were
used according to manufacturers’ instructions. The mouse ELISA kit failed to
recognize kisspeptin in human samples and vice versa.
Statistics
Results are presented as average ±SEM. Student’s t test was used for single
comparisons and ANOVA with Bonferroni adjustment for multiple to calculate
differences between groups. A p value of <0.05was considered significant and
indicated with the * symbol.
ACCESSION CODES
Microarray data are deposited in Gene Expression Omnibus (Barrett et al.,
2005) and accessible through number GSE48815.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.cmet.2014.03.005.
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